The Chicago-based biopharmaceutical firm AbbVie made a major transfer on Feb. 23, as a part of its broader dedication to take a position closely in U.S. analysis and growth over the subsequent 10 years.
AbbVie stated it should make investments$380 million to increase lively pharmaceutical ingredient (API) manufacturing at its hometown campus in North Chicago, Illinois. The transfer is well timed and deepens the White Home’s push to drive provide chains again to the U.S., localize manufacturing, and management rising drug costs.
The undertaking will add two new, superior manufacturing amenities in North Chicago, designed to help AbbVie’s subsequent wave of medicines, notably in neuroscience and metabolic illness. Development is predicted to start in spring 2026, with operations coming on-line later in 2029.
The pharmaceutical large expects the growth to create tons of of high-skilled jobs, from engineers to specialists, ranging from the primary part of firm.
AbbVie’s $100 billion promise to America
That is the primary of many investments anticipated from AbbVie and suits into its bigger $100 billion promise to the Trump administration to reshape analysis within the U.S.
On Jan. 12, AbbVie pledged $100 billion “in U.S.-based research and development and capital investments, including manufacturing, over the next decade.”
AbbVie’s inventory is up 11% yr over yr.
AbbVie
The goal is to make pharmaceutical medication extra reasonably priced for Individuals, increase entry, and guarantee U.S. innovation.
As a part of its funding prospects, the corporate will supply decrease costs to Medicaid and improve its direct-to-patient choices via TrumpRx for a few of its broadly used medicines, together with Alphagan, Combigan, Humira, and Synthroid.
A altering Pharma panorama
This previous yr has seen super motion within the pharmaceutical business. On the one hand, Eli Lilly turned the primary pharma firm to enter the $1 trillion market-cap group.
Alternatively, weight-loss and diabetes-control medication like Ozempic and Wegovy turned extra reasonably priced for Individuals. These medicines additionally turned obtainable at TrumpRx.gov, formally launched on Feb. 5.
Extra Well being Care:
- In case your Medicare plan was canceled, do that now
- Well being care prices are the wild card in year-end tax planning
- 22 million Individuals hit by ACA medical insurance cliff after vote fails
As a part of the continuing progress comes AbbVie, one of many world’s largest biopharmaceutical corporations with operations in additional than 70 international locations. It has a presence in all 50 U.S. states and employs about 29,000 individuals, with greater than 6,000 at its U.S. manufacturing websites.
This $380 million growth in North Chicago is a major addition to this political push, which facilities on decrease prescription prices, reshoring crucial manufacturing to the U.S., and strengthening its provide chain.
AbbVie will rent 300 individuals to help these two new amenities, together with scientists, engineers, manufacturing operators, and lab technicians.
The brand new facility will function state-of-the-art amenities and combine synthetic intelligence to provide the subsequent era of weight problems and neuroscience medicines.
This newest growth highlights how aggressively the pharma large is reshaping its U.S. manufacturing footprint. In September 2025, AbbVie broke floor on the primary part of a $195 million funding, beginning building of an API plant in North Chicago.
The brand new amenities symbolize the second part in its sequence of investments to speed up U.S. manufacturing capabilities. Moreover, on January 12, it introduced an settlement to accumulate a tool manufacturing facility in Tempe, Arizona, with plans to take a position greater than $175 million and create 200 positions on the web site.
Associated: White Home shares key plan to decrease drug prices
